Please use this identifier to cite or link to this item:
Title: DRD1 rs4532 polymorphism: A potential pharmacogenomic marker for treatment response to antipsychotic drugs
Authors: Ota, Vanessa Kiyomi [UNIFESP]
Spindola, Leticia Nery [UNIFESP]
Gadelha, Ary [UNIFESP]
Santos Filho, Airton Ferreira dos [UNIFESP]
Santoro, Marcos Leite [UNIFESP]
Christofolini, Denise Maria
Bellucco, Fernanda Teixeira [UNIFESP]
Ribeiro-dos-Santos, Andrea Kely
Santos, Sidney
Mari, Jair de Jesus [UNIFESP]
Melaragno, Maria Isabel [UNIFESP]
Bressan, Rodrigo Affonseca [UNIFESP]
Cardoso Smith, Marilia de Arruda [UNIFESP]
Belangero, Sintia Iole [UNIFESP]
Universidade Federal de São Paulo (UNIFESP)
Universidade Federal do Pará (UFPA)
Keywords: Schizophrenia
Issue Date: 1-Dec-2012
Publisher: Elsevier B.V.
Citation: Schizophrenia Research. Amsterdam: Elsevier B.V., v. 142, n. 1-3, p. 206-208, 2012.
Abstract: We investigated the association of dopamine receptor D1 gene (DRD1) rs4532 polymorphism with antipsychotic treatment response in schizophrenia. We have analyzed 124 patients with schizophrenia, consisting of 59 treatment resistant (TR) and 65 non-TR. We found an association between G-allele and TR schizophrenia (p=0.001; adjusted OR=2.71). Setting the common AA-genotype as reference, the GG-homozygous presented a five-fold risk compared to AA-homozygous (p=0.010; OR=5.56) with an intermediate result for AG-genotype (p=0.030; adjusted OR=2.64). the DRD1 rs4532 polymorphism showed a dose-response gradient with increased risk for treatment resistance and may be a potential pharmacogenetic marker for antipsychotic drug treatment response. (C) 2012 Elsevier B.V. All rights reserved.
ISSN: 0920-9964
Other Identifiers:
Appears in Collections:Artigo

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.